Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$3.17M$3.17M−39.1% vs Q2 2025 Net Income-$24.47M-$24.47MN/M vs Q2 2025 EPS Diluted-$0.40-$0.40N/M vs Q2 2025 Operating Income-$26,392,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$25,842,000N/M Margins · derivedOperating margin-833.9%−129.5 pt vs Q2 2025
Net margin-773.2%−131.3 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end